Takeda has decided to withdraw its cancer drug Exkivity from the market, after a trial that was supposed to confirm its efficacy failed to deliver a positive result.
A £1 billion development aimed at creating a major centre for cancer research and treatment in South London has taken a step forwards with the selection of preferred bidde
The FDA has started a priority review of Regeneron’s CD20xCD3 bispecific antibody odronextamab, seeking a broader label than other drugs in the class.
In the Middle East and North Africa, cancer is growing at an alarming rate, and – as Economist Impact notes – the region is on the cusp of a demographic transition, with UNICEF predicting t
Imagine being told just after giving birth to a new baby that you have cancer.
Editor's Picks
